Bray F, Laversanne M, Weiderpass E, Soerjomataram I. The ever-increasing importance of cancer as a leading cause of premature death worldwide. Cancer. 2021;127(16):3029–30.

Article  PubMed  Google Scholar 

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA-Cancer J Clin. 2021;71(3):209–49.

Article  PubMed  Google Scholar 

Pernar CH, Ebot EM, Wilson KM, Mucci LA. The epidemiology of prostate cancer. Cold Spring Harb Perspect Med. 2018;8(12): a030361.

Article  PubMed  PubMed Central  Google Scholar 

Rawla P. Epidemiology of prostate cancer. World J Oncol. 2019;10(2):63–89.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mathur P, Sathishkumar K, Chaturvedi M, Das P, Sudarshan KL, Santhappan S, Nallasamy V, John A, Narasimhan S, Roselind FS. Cancer Statistics, 2020: Report From National Cancer Registry Programme. India JCO Glob Oncol. 2020;2020(6):1063–75.

Article  Google Scholar 

Pinsky PF, Miller E, Prorok P, Grubb R, Crawford ED, Andriole G. Extended follow-up for prostate cancer incidence and mortality among participants in the Prostate, Lung, Colorectal and Ovarian randomized cancer screening trial. BJU Int. 2019;123(5):854–60.

Article  PubMed  Google Scholar 

Liu X, Zhang Y, Duan H, Yang L, Sheng C, Fan Z, Liu Y, Gao Y, Wang X, Zhang Q, et al. Risk-stratified multi-round PSA screening for prostate cancer integrating the screening reference level and subgroup-specific progression indicators. Eur J MedRes. 2023;28(1):257.

CAS  Google Scholar 

Cuzick J. The importance of long-term follow up of participants in clinical trials. Br J Cancer. 2023;128(3):432–8.

Article  PubMed  Google Scholar 

Zeigler-Johnson C, McDonald AC, Pinheiro P, Lynch S, Taioli E, Joshi S, Alpert N, Baudin J, Joachim C, Deloumeaux J, et al. Trends in prostate cancer incidence among Black men in the Caribbean and the United States. Prostate. 2023;83(12):1207–16.

Article  PubMed  Google Scholar 

Brawley OW. Trends in prostate cancer in the United States. J Natl Cancer Inst Monogr. 2012;2012(45):152–6.

Article  PubMed  PubMed Central  Google Scholar 

Smith-Palmer J, Takizawa C, Valentine W. Literature review of the burden of prostate cancer in Germany, France, the United Kingdom and Canada. BMC Urol. 2019;19(1):19.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Jain MA, Sapra A: Cancer Prostate Screening. In StatPearls. Treasure Island (FL): StatPearls Publishing. Copyright © 2021, StatPearls Publishing LLC.; 2021.

Kaler J, Hussain A, Haque A, Naveed H, Patel S. A comprehensive review of pharmaceutical and surgical interventions of prostate cancer. Cureus. 2020;12(11):e11617–e11617.

PubMed  PubMed Central  Google Scholar 

Gann PH. Risk factors for prostate cancer. Rev Urol. 2002;4(5):S3–10.

PubMed  PubMed Central  Google Scholar 

Merriel SWD, Funston G, Hamilton W. Prostate cancer in primary care. Adv Ther. 2018;35(9):1285–94.

Article  PubMed  PubMed Central  Google Scholar 

Kohada Y, Hieda K, Miyamoto S, Tasaka R, Asami A, Akiyama K, Sakamoto Y, Kirishima F, Saito K, Fukushima T, et al. Retrospective evaluation of the improvement in the urinary status-related quality of life after robot-assisted radical prostatectomy. Int J Urol. 2023. https://doi.org/10.1111/iju.15251.

Article  PubMed  Google Scholar 

Pantwalawalkar J, Chandankar S, Tade R, Khan Z, Shaikh M, Powar T, Patil P, Sugandhi V, Nangare S. Graphene quantum dot based ultrasensitive probe for biosensing of prostate cancer biomarkers: current updates and future challenges. Adv Nat Sci: Nanosci Nanotechnol. 2022;13(1): 013001.

Google Scholar 

Haglind E, Carlsson S, Stranne J, Wallerstedt A, Wilderäng U, Thorsteinsdottir T, Lagerkvist M, Damber J-E, Bjartell A, Hugosson J, et al. Urinary incontinence and erectile dysfunction after robotic versus open radical prostatectomy: a prospective, controlled, nonrandomised trial. Eur Urol. 2015;68(2):216–25.

Article  PubMed  Google Scholar 

Force UPST. Screening for prostate cancer: US preventive services task force recommendation statement. JAMA. 2018;319(18):1901–13.

Article  Google Scholar 

Tu X, Liu Z, Chang T, Qiu S, Xu H, Bao Y, Yang L, Wei Q. Transperineal magnetic resonance imaging-targeted biopsy may perform better than transrectal route in the detection of clinically significant prostate cancer: systematic review and meta-analysis. Clin Genitourin Cancer. 2019;17(5):e860–70.

Article  PubMed  Google Scholar 

Pirola GM, Castellani D, Orecchia L, Giulioni C, Gubbiotti M, Rubilotta E, Maggi M, Teoh JYC, Gauhar V, Naselli A. Transperineal US-MRI fusion-guided biopsy for the detection of clinical significant prostate cancer: a systematic review and meta-analysis comparing cognitive and software-assisted technique. Cancers. 2023;15(13):3443.

Article  PubMed  PubMed Central  Google Scholar 

Xie J, Jin C, Liu M, Sun K, Jin Z, Ding Z, Gong X. MRI/transrectal ultrasound fusion-guided targeted biopsy and transrectal ultrasound-guided systematic biopsy for diagnosis of prostate cancer: a systematic review and meta-analysis. Front Oncol. 2022;12: 880336.

Article  PubMed  PubMed Central  Google Scholar 

Gordetsky J, Epstein J. Grading of prostatic adenocarcinoma: current state and prognostic implications. Diagn Pathol. 2016;11(1):25.

Article  PubMed  PubMed Central  Google Scholar 

Rouvière O, Puech P, Renard-Penna R, Claudon M, Roy C, Mège-Lechevallier F, Decaussin-Petrucci M, Dubreuil-Chambardel M, Magaud L, Remontet L, et al. Use of prostate systematic and targeted biopsy on the basis of multiparametric MRI in biopsy-naive patients (MRI-FIRST): a prospective, multicentre, paired diagnostic study. Lancet Oncol. 2019;20(1):100–9.

Article  PubMed  Google Scholar 

Puche-Sanz I, Rodríguez-Martínez A, Garrido-Navas MC, Robles-Fernández I, Vázquez-Alonso F, Álvarez Cubero MJ, Lorente-Acosta JA, Serrano-Fernández MJ, Cózar-Olmo JM. Liquid biopsy and prostate cancer. Current evidence applied to clinical practice. Actas Urol Esp (Engl Ed). 2020;44(3):139–47.

Article  CAS  PubMed  Google Scholar 

Saranyutanon S, Srivastava SK, Pai S, Singh S, Singh AP. Therapies targeted to androgen receptor signaling axis in prostate cancer: progress, challenges, and hope. Cancers (Basel). 2020;12(1):51.

Article  CAS  Google Scholar 

Ng K, Smith S, Shamash J. Metastatic Hormone-Sensitive Prostate Cancer (mHSPC): advances and treatment strategies in the first-line setting. Oncol Ther. 2020;8(2):209–30.

Article  PubMed  PubMed Central  Google Scholar 

Sumanasuriya S, De Bono J. Treatment of advanced prostate cancer-a review of current therapies and future promise. Cold Spring Harb Perspect Med. 2018;8(6):35.

Article  Google Scholar 

Bill-Axelson A, Holmberg L, Garmo H, Taari K, Busch C, Nordling S, Häggman M, Andersson S-O, Andrén O, Steineck G, et al. Radical prostatectomy or watchful waiting in prostate cancer — 29-year follow-up. N Engl J Med. 2018;379(24):2319–29.

Article  PubMed  Google Scholar 

Groarke A, Curtis R, Skelton J, Groarke JM. Quality of life and adjustment in men with prostate cancer: Interplay of stress, threat and resilience. PLoS ONE. 2020;15(9): e0239469.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yabroff KR, Zhao J, Chen MH, Hoque J, Arias G, Han X, Zheng Z. Financial hardship and psychosocial well-being and quality of life among prostate cancer survivors in the United States. Urol Oncol: Semin Orig Invest. 2023;8:56.

Google Scholar 

Korfage IJ, Hak T, de Koning HJ, Essink-Bot M-L. Patients’ perceptions of the side-effects of prostate cancer treatment—a qualitative interview study. Soc Sci Med. 2006;63(4):911–9.

Article  PubMed  Google Scholar 

Ho MY, Mackey JR. Presentation and management of docetaxel-related adverse effects in patients with breast cancer. Cancer Manage Res. 2014;6:253–9.

Article  Google Scholar 

Baker J, Ajani J, Scotté F, Winther D, Martin M, Aapro MS, von Minckwitz G. Docetaxel-related side effects and their management. Eur J Oncol Nurs. 2008;12(3):253–68.

Article  PubMed  Google Scholar 

Sperlich C, Saad F. Optimal management of patients receiving cabazitaxel-based chemotherapy. Can Urol Assoc J. 2013;7(1):S18-24.

PubMed  PubMed Central  Google Scholar 

Mellado B, Jimenez N, Marin-Aguilera M, Reig O. Diving into cabazitaxel’s mode of action: more than a taxane for the treatment of castration-resistant prostate cancer patients. Clin Genitourin Cancer. 2016;14(4):265–70.

Article  PubMed  Google Scholar 

Fox EJ. Mechanism of action of mitoxantrone. Neurology. 2004;63(12 Suppl 6):S15-18.

Article  CAS  PubMed  Google Scholar 

Cochrane ZR. Uses and risks of mitoxantrone. https://www.medicalnewstodaycom/articles/322211. Accessed 15 Jan 2019.

Li R, Evaul K, Sharma KK, Chang KH, Yoshimoto J, Liu J, Auchus RJ, Sharifi N. Abiraterone inhibits 3β-hydroxysteroid dehydrogenase: a rationale for increasing drug exposure in castration-resistant prostate cancer. Clin Cancer Res. 2012;18(13):3571–9.

Article  CAS  PubMed  Google Scholar 

Bedussi F, Galli D, Fragni M, Valcamonico F, Rossini E, Dalla Volta A, Vezzoli S, Roca E, Ferrari V, Lazzari B, et al. Amiloride is effective in the management of abiraterone-induced mineralocorticoid excess syndrome without interfering with its antineoplastic activity. Pharmacol. 2017;100(5–6):261–8.

Article  CAS  Google Scholar 

Merseburger AS, Haas GP, von Klot CA. An update on enzalutamide in the treatment of prostate cancer. Ther Adv Urol. 2015;7(1):9–21.

Article